SCHEMBL18150679

SCHEMBL18150679

O=C1CCC(c2ccccn2)N1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 7/20 0.58
DDB1 Q16531 4/20 0.58
ALDH1A1 P00352 4/20 0.43
KMT2A Q03164 3/20 0.43
MAPT P10636 2/20 0.43
RAB9A P51151 2/20 0.43
NPC1 O15118 1/20 0.43
KDM4E B2RXH2 3/20 0.39
MEN1 O00255 2/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HSD17B10 Q99714 1/20 0.39
GSK3B P49841 1/20 0.39
PARP1 P09874 1/20 0.37
PARP2 Q9UGN5 1/20 0.37
TSHR P16473 1/20 0.37
GFER P55789 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11164416 0.83 CRBN (0.55) CRBNDDB1ALDH1A1KMT2AMAPT
SCHEMBL18162847 0.79 DDB1 (0.43) CRBNDDB1ALDH1A1KMT2AMAPT
SCHEMBL9024567 0.78 CRBN (0.52) CRBNDDB1ALDH1A1KMT2AMAPT
SCHEMBL16037063 0.77 DDB1 (0.41) CRBNDDB1ALDH1A1KMT2ARAB9A
SCHEMBL29746175 0.77 DDB1 (0.41) CRBNDDB1ALDH1A1KMT2ARAB9A
SCHEMBL16268284 0.77 DDB1 (0.44) CRBNDDB1ALDH1A1KMT2AMAPT
SCHEMBL30640402 0.76 DDB1 (0.36) CRBNDDB1PARP1PARP2
SCHEMBL29967570 0.75 CRBN (0.56) CRBNDDB1ALDH1A1KMT2AMAPT
SCHEMBL1440419 0.75 ALDH1A1 (0.42) CRBNDDB1ALDH1A1KMT2AMAPT
SCHEMBL1439472 0.75 ALDH1A1 (0.42) CRBNDDB1ALDH1A1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3750885-A1 COMPOUND HAVING BET INHIBITORY ACTIVITY AND PREPARATION METHOD AND USE THEREFOR Shanghai Haihe Pharmaceutical Co., Ltd. (CN) 2020-12-16 EP disclosed
EP-3750885-A1 COMPOUND HAVING BET INHIBITORY ACTIVITY AND PREPARATION METHOD AND USE THEREFOR Shanghai Haihe Pharmaceutical Co., Ltd. (CN) 2020-12-16 EP disclosed
CN-111683932-A Compound with BET inhibition activity, preparation method and application thereof 上海海和药物研究开发有限公司 2020-09-18 CN disclosed
WO-2019154329-A1 COMPOUND HAVING BET INHIBITORY ACTIVITY AND PREPARATION METHOD AND USE THEREFOR 上海海和药物研究开发有限公司 2019-08-15 WO disclosed
WO-2019154329-A1 COMPOUND HAVING BET INHIBITORY ACTIVITY AND PREPARATION METHOD AND USE THEREFOR 上海海和药物研究开发有限公司 2019-08-15 WO disclosed
US-10266532-B2 Tricyclic modulators of TNF signaling ABBVIE INC. (US) 2019-04-23 US disclosed
US-10266532-B2 Tricyclic modulators of TNF signaling ABBVIE INC. (US) 2019-04-23 US disclosed
US-20180179198-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2018-06-28 US disclosed
US-20180179198-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2018-06-28 US disclosed
US-20180179198-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2018-06-28 US disclosed
EP-3288939-A1 TRICYCLIC MODULATORS OF TNF SIGNALING AbbVie Inc. (US) 2018-03-07 EP disclosed
US-9856253-B2 Tricyclic modulators of TNF signaling ABBVIE, INC. (US) 2018-01-02 US disclosed
US-9856253-B2 Tricyclic modulators of TNF signaling ABBVIE, INC. (US) 2018-01-02 US disclosed
US-20160304517-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2016-10-20 US disclosed
US-20160304517-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2016-10-20 US disclosed
US-20160304517-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2016-10-20 US disclosed
WO-2016168641-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. (US) 2016-10-20 WO disclosed
WO-2016168641-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. (US) 2016-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160304517-A1 TRICYCLIC MODULATORS OF TNF SIGNALING TNF, TNFRSF1A, CD40 CRBN 2641/4885DDB1 2913/4885ALDH1A1 1896/4885
US-10266532-B2 Tricyclic modulators of TNF signaling TNF, TNFRSF1A, CD40 CRBN 2641/4885DDB1 2913/4885ALDH1A1 1896/4885
US-20180179198-A1 TRICYCLIC MODULATORS OF TNF SIGNALING TNF, TNFRSF1A, CD40 CRBN 2641/4885DDB1 2913/4885ALDH1A1 1896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.